Loading…
TG Therapeutics, Inc. is projected to rise to $86.75 by 2027, a +47% move from its current price of $59.06. TGTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $57.66 | $59.08 | $60.54 | +0.03% |
| Jul 13 | $57.10 | $59.10 | $61.17 | +0.06% |
| Jul 14 | $56.67 | $59.12 | $61.67 | +0.10% |
| Jul 15 | $56.32 | $59.14 | $62.09 | +0.13% |
| Jul 16 | $56.02 | $59.15 | $62.47 | +0.16% |
| Jul 17 | $55.74 | $59.17 | $62.81 | +0.19% |
| Jul 18 | $55.50 | $59.19 | $63.13 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $55.50 | $59.19 | $63.13 | +0.22% |
| Week 2 | $54.15 | $59.32 | $64.99 | +0.45% |
| Week 3 | $53.18 | $59.46 | $66.48 | +0.67% |
| Week 4 | $52.38 | $59.59 | $67.79 | +0.90% |
| Week 5 | $51.71 | $59.72 | $68.99 | +1.12% |
| Week 6 | $51.11 | $59.86 | $70.10 | +1.35% |
| Week 7 | $50.58 | $59.99 | $71.15 | +1.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines.
The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
TG Therapeutics, Inc. (TGTX) is currently priced at $59.06 per share and has a market capitalization of $9.04B. It is ranked 990.
The current price outlook is reflected in the forecast, with the 2026 average price of $59.06, rising to $86.88 in 2027, $111.48 in 2028, $127.72 in 2029, and $146.55 in 2030.
From 2027 onward the forecast carries a BULLISH sentiment, with averages climbing to $170.57 in 2031, $181.58 in 2032, $212.12 in 2033, $264.60 in 2034, $304.64 in 2035, $458.90 in 2040, and $1,132.77 in 2050, while the max values reach as high as $1,998.75 in 2050.
A major floor 54.4% below — a decisive break under it would weaken the trend.
The nearest floor, 38.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 24.2% above — clearing it would confirm fresh momentum.
Key TGTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TGTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $57.39 | Buy | $57.14 | Buy |
| MA 10 | $56.03 | Buy | $55.96 | Buy |
| MA 20 | $53.95 | Buy | $53.26 | Buy |
| MA 50 | $45.33 | Buy | $47.03 | Buy |
| MA 100 | $38.59 | Buy | $41.71 | Buy |
| MA 200 | $35.27 | Buy | $37.59 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.73 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 94.84 | Neutral |
| Williams %R (14) | -33.74 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 5.90 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 66.26 | Neutral |
| TRIX (15) | 1.20 | Buy |
| Awesome (5,34) | 9.19 | Buy |
| Ultimate (7,14,28) | 63.08 | Neutral |
| Momentum (10) | 3.49 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 58.89 | Buy |
| ADX (14) | 45.46 | Buy |
| ATR (14) | 1.22 | Info |
The 30-day technical picture is bullish.
RSI14 is 80, SMA50 is $44.88, and SMA200 is $35.16. Support is at $36.64 and resistance at $59.06. The 30-day range runs from $50.43 to $69.17. Annualized volatility is 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.94 | $59.06 | $81.20 | 0% | Neutral | |
| $69.75 | $86.75 | $113.72 | +47% | Bullish | |
| $87.73 | $111.84 | $151.59 | +89% | Bullish | |
| $98.37 | $127.97 | $178.08 | +117% | Bullish | |
| $110.89 | $146.86 | $208.94 | +149% | Bullish | |
| $127.16 | $171.18 | $248.31 | +190% | Bullish | |
| $132.95 | $181.69 | $268.19 | +208% | Bullish | |
| $153.04 | $212.13 | $318.10 | +259% | Bullish | |
| $188.59 | $264.95 | $403.13 | +349% | Bullish | |
| $214.58 | $305.34 | $470.93 | +417% | Bullish | |
| $304.85 | $459.62 | $750.35 | +678% | Bullish | |
| $683.73 | $1,137.29 | $2,018.02 | +18.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.94 | $59.06 | $70.34 | +0.00% |
| August 2026 | $49.94 | $58.79 | $70.94 | -0.46% |
| September 2026 | $51.34 | $60.81 | $74.11 | +3.43% |
| October 2026 | $53.08 | $63.21 | $77.68 | +3.95% |
| November 2026 | $53.17 | $63.59 | $78.70 | +0.61% |
| December 2026 | $54.27 | $65.18 | $81.20 | +2.50% |
Click any year to see its month-by-month TGTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TG Therapeutics, Inc.'s 2026 outlook centres on $59.06, within a $26.94 to $81.20 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TGTX could reach as high as $113.72, with a base case around $86.75 and support toward $69.75 — roughly +47% from $59.06. Buyers look set to stay in control over this stretch.
Expect TGTX to range from $87.73 to $151.59 through 2028. The $111.84 average target implies a +89% move from current prices. That is up +29% on the projected 2027 average. Momentum favours further upside here.
The TGTX price prediction for 2029 points to an average of $127.97 (low $98.37, high $178.08) — a potential gain of +117% on today's $59.06. Buyers look set to stay in control over this stretch.
In 2030, TGTX is projected to trade between $110.89 and $208.94, averaging $146.86 — a potential gain of +149% from today's $59.06. That is up +15% on the projected 2029 average. Momentum favours further upside here.
TG Therapeutics, Inc.'s 2031 outlook centres on $171.18, within a $127.16 to $248.31 range. That is up +17% on the projected 2030 average. That marks a +190% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TGTX could reach as high as $268.19, with a base case around $181.69 and support toward $132.95 — roughly +208% from $59.06. Momentum favours further upside here.
Expect TGTX to range from $153.04 to $318.10 through 2033. The $212.13 average target implies a +259% move from current prices. That is up +17% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TGTX price prediction for 2034 points to an average of $264.95 (low $188.59, high $403.13) — a potential gain of +349% on today's $59.06. Momentum favours further upside here.
In 2035, TGTX is projected to trade between $214.58 and $470.93, averaging $305.34 — a potential gain of +417% from today's $59.06. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
TG Therapeutics, Inc.'s 2040 outlook centres on $459.62, within a $304.85 to $750.35 range. That is up +51% on the projected 2035 average. That marks a +678% change versus current levels. Momentum favours further upside here.
By 2050, TGTX could reach as high as $2,018.02, with a base case around $1,137.29 and support toward $683.73 — roughly +18.3x from $59.06. Buyers look set to stay in control over this stretch.
Investing $1,000 in TGTX today (≈ 16.931934 TGTX) could be worth
$19,256.44
+$18,256.44 (+1826%) by 2050 · US Dollar
Based on the average projected TGTX price of $1,137.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TGTXwould be worth at today's price.
$1,000 invested in TGTX on Jul 10, 2025 (≈ 26.546325 TGTX) would be worth
$1,567.83
+$567.83 (+56.8%) today · 1.57× · US Dollar
Based on a TGTX entry price of $37.67 vs. today's $59.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $53.31 | $1,107.86 | +10.8% |
| 1 month ago | $46.62 | $1,266.84 | +26.7% |
| 3 months ago | $33.73 | $1,750.96 | +75.1% |
| 6 months ago | $27.72 | $2,130.59 | +113.1% |
| 1 year ago | $37.67 | $1,567.83 | +56.8% |
| All time (5.0y) ago | $39.32 | $1,502.03 | +50.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TGTX forecast.
Our base-case forecast reaches $120.00 around 2029.
Implied market cap at $120.00: $18.37B
The multi-year forecast shows a trajectory from a 2026 average price of $59.06 with neutral sentiment to a bullish outlook through 2035 and beyond. In 2026 the min is $26.94 and the max is $81.31 (ROI 0, sentiment NEUTRAL).
Key milestones include a 2030 average price of $146.55 with ROI 148.1 and bullish sentiment. The forecast also flags continued growth with a 2040 average of $458.90 (ROI 677) and a 2050 average of $1,132.77 (ROI 1818).
Across 2031 through 2035 the averages rise from $170.57 to $304.64, and the later horizon shows bullish sentiment with a max path reaching $316.94 in 2033, $401.06 in 2034, $467.96 in 2035, $745.67 in 2040, and $1,998.75 in 2050. These are estimates, not guarantees, and carry inherent uncertainty.
Tap a question to reveal the answer.
2030_avg: $146.55; min $110.92; max $207.89; ROI 148.1; sentiment BULLISH.
Forecast shows a neutral year in 2026 with an avg price of $59.06, then bullish sentiment from 2027 onward with rising averages to 2050 (avg $1,132.77, max $1,998.75). The data also shows increasing sentiment from 2027 through 2050.
Yes, the maximums in later years reach above $200: 2030 max $207.89, 2031 max $246.63, 2032 max $267.11, 2033 max $316.94, 2034 max $401.06, 2035 max $467.96, 2040 max $745.67, 2050 max $1,998.75.
Low $50.43, High $69.17.
Current price $59.06; market cap $9.04B.
TG Therapeutics, Inc. Community Discussion
0Share your TG Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.